Effect of Losartan discontinuation on treatment of anemia in hemodialysis patients

The effect of discontinuation of angiotensin-II receptor blocker on therapeutic effect of synthetic erythropoietin on anemia modification in hemodialysis patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190127042516N1

Enrollment

Registered

2019-02-13

Start date

2019-02-09

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease. Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease

Interventions

Intervention 1: Intervention group: Discontinuation of Losartan. Intervention 2: Control group: Hemodialysis patients on Losartan for at least 3 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All hypertensive patients with ESRD on regular hemodialysis consist of 3 4-hours session per week. Use of Losartan at least the last three months

Exclusion criteria

Exclusion criteria: Dosage alteration for rHuEPO, ferrous sulfate and Carnitine supplementation. Serious infection leading hospitalization Obvious bleeding Transfusion Surgery CRP>10 mg/L Serum Ferritin <100 ng/ml Any alteration in hemodialysis dosage/time

Design outcomes

Primary

Measure	Time frame
Hemoglobin increment. Timepoint: Before intervention and 3 months after discontinuation of Losartan. Method of measurement: Cell Counter Mindry BC 3000Plus machine.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmood Reza Khazaei

Islamic Azad University

khazaeem@mshdiau.ac.ir+98 51 3840 1279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026